Ion Beam Applications SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ion Beam Applications SA Closes Sale of Its Cisbio Bioassays Business Unit
Ion Beam Applications SA announced the closing of the sale of 100% of its business unit Cisbio Bioassays. The closing has led to a payment to the Company of EUR 16.3 million. In addition, the contract includes an earn out of EUR 1 million based on Cisbio Bioassays' full year 2013 consolidated results, an earn out of EUR 1.4 million if and when certain long term receivables are collected (expected in 2015) and a vendor loan of EUR 7.5 million repayable over a maximum of seven years based on an allocation of 60% of the EBIT above a certain threshold. The vendor loan will accrue interest at market conditions. Any unpaid balance after seven years is lost. Cisbio Bioassays activity, and impacts of the transactions, will have a positive effect on the Company's 2013 net results of approximately EUR 3 million. In order to maintain its focus on its proton therapy, accelerators and dosimetry activities, the Company has chosen not to exercise its option to keep a minority stake in the Cisbio Bioassays activity.
Latest Key Developments in Advanced
- Thermo Fisher Scientific Inc raises FY 2014 guidance
- Illumina Inc raises FY 2014 outlook
- Vascular Solutions Inc gives Q2 2014 guidance in line with analysts' estimates; reaffirms FY 2014 revenue guidance; lowers FY 2014 EPS guidance
- Quidel Corp receives FDA Clearance for its Lyra Molecular PCR assay for the Detection of infections from Pyogenic Streptococcus Group A and C or G
- Share this
- Digg this